MX2017008063A - Formas amorfas y polimorficas de (r)-2-hidroxi-2-metil-4-(2,4,5-tr imetil-3,6-dioxociclohexa-1,4-dienil)butanamida. - Google Patents

Formas amorfas y polimorficas de (r)-2-hidroxi-2-metil-4-(2,4,5-tr imetil-3,6-dioxociclohexa-1,4-dienil)butanamida.

Info

Publication number
MX2017008063A
MX2017008063A MX2017008063A MX2017008063A MX2017008063A MX 2017008063 A MX2017008063 A MX 2017008063A MX 2017008063 A MX2017008063 A MX 2017008063A MX 2017008063 A MX2017008063 A MX 2017008063A MX 2017008063 A MX2017008063 A MX 2017008063A
Authority
MX
Mexico
Prior art keywords
polymorphic
amorphous forms
dioxocyclohexa
butanamide
dienyl
Prior art date
Application number
MX2017008063A
Other languages
English (en)
Inventor
Mollard Paul
R Cornell Christopher
E Wesson Kieron
Giannousis Peter
SUCHIT Shazad
Mirmehrabi Mahmoud
Original Assignee
Bioelectron Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioelectron Tech Corp filed Critical Bioelectron Tech Corp
Publication of MX2017008063A publication Critical patent/MX2017008063A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Abstract

La presente invención se refiere a formas polimórficas y amorfas de anhidrato, hidrato, y solvatos de (R)-2-hidroxi-2-metil-4-(2,4, 5-trimetil-3,6-dioxociclohexa-1,4-dienil)butanamida y métodos para usar tales composiciones para tratar o suprimir trastornos por estrés oxidativo, que incluyen trastornos mitocondriales, trastornos de procesamiento de energía alterada, enfermedades neurodegenerativas y enfermedades del envejecimiento. Además, se describen métodos para elaborar tales formas polimórficas y amorfas.
MX2017008063A 2014-12-16 2015-12-16 Formas amorfas y polimorficas de (r)-2-hidroxi-2-metil-4-(2,4,5-tr imetil-3,6-dioxociclohexa-1,4-dienil)butanamida. MX2017008063A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092743P 2014-12-16 2014-12-16
US201562133276P 2015-03-13 2015-03-13
PCT/US2015/066211 WO2016100579A1 (en) 2014-12-16 2015-12-16 Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

Publications (1)

Publication Number Publication Date
MX2017008063A true MX2017008063A (es) 2017-09-28

Family

ID=55071223

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017008063A MX2017008063A (es) 2014-12-16 2015-12-16 Formas amorfas y polimorficas de (r)-2-hidroxi-2-metil-4-(2,4,5-tr imetil-3,6-dioxociclohexa-1,4-dienil)butanamida.
MX2021009340A MX2021009340A (es) 2014-12-16 2017-06-16 Formas amorfas y polimorficas de (r)-2-hidroxi-2-metil-4-(2,4,5- trimetil-3,6-dioxociclohexa-1,4-dienil)butanamida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009340A MX2021009340A (es) 2014-12-16 2017-06-16 Formas amorfas y polimorficas de (r)-2-hidroxi-2-metil-4-(2,4,5- trimetil-3,6-dioxociclohexa-1,4-dienil)butanamida.

Country Status (21)

Country Link
US (5) US10251847B2 (es)
EP (2) EP3233786B1 (es)
JP (4) JP6810692B2 (es)
KR (1) KR102626895B1 (es)
CN (2) CN114702406A (es)
AU (3) AU2015364640B2 (es)
BR (1) BR112017012988B1 (es)
CA (1) CA2971252A1 (es)
DK (1) DK3233786T3 (es)
ES (1) ES2912585T3 (es)
HU (1) HUE058877T2 (es)
IL (1) IL252953A0 (es)
MX (2) MX2017008063A (es)
NZ (1) NZ733528A (es)
PL (1) PL3233786T3 (es)
PT (1) PT3233786T (es)
RU (1) RU2770091C2 (es)
SG (2) SG11201704968XA (es)
SI (1) SI3233786T1 (es)
WO (1) WO2016100579A1 (es)
ZA (1) ZA201704639B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471530B1 (en) 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EA038941B1 (ru) 2007-11-06 2021-11-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
EP2963006B1 (en) 2008-10-28 2018-10-17 BioElectron Technology Corporation Composition containing alpha-tocotrienol quinone,and intermediates thereof
WO2013013078A1 (en) 2011-07-19 2013-01-24 Edison Pharmeceuticals, Inc. Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
ES2912585T3 (es) 2014-12-16 2022-05-26 Ptc Therapeutics Inc Formas polimórficas y amorfas de la (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociclohexa-1,4-dienil)butanamida
US10745371B2 (en) 2015-12-16 2020-08-18 Ptc Therapeutics, Inc. Methods for enriching alpha-tocotrienol from mixed tocol compositions
CN113024369A (zh) 2015-12-17 2021-06-25 Ptc医疗公司 用于治疗氧化应急障碍的化合物
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
DK3866772T3 (da) 2018-10-17 2024-01-15 Ptc Therapeutics Inc 2,3,5-trimethyl-6-nonylcyclohexa-2,5-dien-1,4-dion til undertrykkelse og behandling af alpha-synucleinopathier, tauopathier og andre lidelser
KR20240032997A (ko) 2021-07-08 2024-03-12 피티씨 테라퓨틱스, 인크. 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온을 포함하는 약제학적 조성물
WO2024058099A1 (ja) * 2022-09-12 2024-03-21 住友ファーマ株式会社 懸濁用顆粒
WO2024071372A1 (ja) * 2022-09-30 2024-04-04 住友ファーマ株式会社 Ｔｒｏｌｏｘアミドの酸化的開裂法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018799A (en) 1973-11-19 1977-04-19 Hoffmann-La Roche Inc. Antioxidant chroman compounds
US4026907A (en) 1973-11-19 1977-05-31 Hoffmann-La Roche Inc. Antioxidant chroman compounds
JPS5640651A (en) 1979-09-12 1981-04-16 Takeda Chem Ind Ltd Quinone compound and its preparation
US5272180A (en) 1987-07-29 1993-12-21 Takeda Chemical Industries, Ltd. Cell proliferation inhibitor
US5348973A (en) 1990-10-09 1994-09-20 Rhone-Poulenc Chimie Resolution of hydroxychroman-2-carboxylic acid esters by enantiomeric hydrolysis
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
CA2207333C (en) 1994-12-28 2006-10-17 Janssen Pharmaceutica, Naamloze Vennootschap Use of nebivolol as an anti-atherogenic
EP0846109B1 (en) 1995-08-21 2002-07-24 Takeda Chemical Industries, Ltd. Quinone compound, its production and use
US6232060B1 (en) 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
CA2252519A1 (en) 1996-07-11 1998-01-22 Keisuke Hirai Use of idebenone and analogues against beta amyloid induced cytotoxicity
AU716992B2 (en) 1996-09-19 2000-03-16 Japan Energy Corporation Hydroquinone derivative and pharmaceutical use thereof
JP3093170B2 (ja) 1996-09-19 2000-10-03 株式会社ジャパンエナジー ヒドロキノン誘導体及びその医薬用途
JP3913329B2 (ja) * 1997-09-11 2007-05-09 株式会社クラレ （±）−クロマンカルボン酸の光学分割法
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6426362B1 (en) 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
WO2002012221A1 (fr) 2000-08-03 2002-02-14 Kuraray Co., Ltd. Procede de resolution optique de l'acide (±)-6-hydroxy-2,5,7,8,-tetramethyle de coumarone-2-carboxylique
WO2002047680A2 (en) 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US7034054B2 (en) 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
NZ513547A (en) 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
US7119117B2 (en) 2001-08-21 2006-10-10 Galileo Pharmaceuticals, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
US20030144219A1 (en) 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
US6667330B2 (en) 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
US7078541B2 (en) 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
GB0204232D0 (en) 2002-02-22 2002-04-10 Isis Innovation Assay
DE60211875T2 (de) 2002-07-01 2006-10-26 Santhera Pharmaceuticals (Schweiz) Ag Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia
CA2504334A1 (en) 2002-10-30 2004-05-21 Galileo Pharmaceuticals, Inc. Identifying therapeutic compounds based on their physical-chemical properties
EP1454627A1 (en) 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
WO2005032544A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Treatment of mitochondrial diseases
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
FR2875803B1 (fr) 2004-09-24 2006-11-24 Catalys Sarl Preparation de composes phenol-amides a proprietes antioxydantes
EP2471530B1 (en) 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EA021818B1 (ru) 2005-09-15 2015-09-30 Эдисон Фармасьютикалз, Инк. Варианты хвостовой части редокс-активных лекарственных средств для лечения митохондриальных болезней и модуляция биомаркера энергетического обмена q10
US20070208086A1 (en) 2006-02-15 2007-09-06 The Regents Of The University Of California Ubiquinone analogs and methods of use
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
EP2088144B1 (en) * 2006-10-26 2011-12-28 Mitsubishi Gas Chemical Company, Inc. Method of producing s-(-)-6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid
US20100056429A1 (en) 2007-01-10 2010-03-04 Miller Guy M Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
EA038941B1 (ru) 2007-11-06 2021-11-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
WO2009088572A2 (en) 2008-01-07 2009-07-16 Centocor, Inc. Method of treating erythropoietin hyporesponsive anemias
US8952071B2 (en) 2008-01-08 2015-02-10 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
JP2011513420A (ja) * 2008-03-05 2011-04-28 エジソン ファーマシューティカルズ， インコーポレイテッド レドックス活性治療薬を用いる聴覚機能障害および平衡機能障害の処置
CA2717734A1 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
EP2310038A4 (en) 2008-05-15 2012-03-14 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCE DISORDERS WITH COMPOUNDS HAVING ERYTHROPOIETIN ACTIVITY
CA2724841A1 (en) 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
JP5266875B2 (ja) 2008-05-23 2013-08-21 三菱瓦斯化学株式会社 有機カルボン酸エステルからの光学活性有機カルボン酸の製造方法
US8716486B2 (en) 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US20100010100A1 (en) 2008-07-09 2010-01-14 Hinman Andrew W Dermatological compositions with anti-aging and skin even-toning properties
WO2010014758A1 (en) 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress
US20100029784A1 (en) 2008-07-30 2010-02-04 Hinman Andrew W Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
CA2736250C (en) 2008-09-10 2016-12-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
EP2963006B1 (en) 2008-10-28 2018-10-17 BioElectron Technology Corporation Composition containing alpha-tocotrienol quinone,and intermediates thereof
BRPI1015006A2 (pt) 2009-04-28 2019-09-24 Ampere Life Sciences Inc uso tópico, periocular, ou intraocular de tocotrienóis para o tratamento de doenças oftálmicas
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
JP2012525397A (ja) 2009-04-28 2012-10-22 エジソン ファーマシューティカルズ， インコーポレイテッド 眼科疾患を治療するためのトコトリエノールキノンの製剤
JP2012531411A (ja) 2009-06-25 2012-12-10 アンペア ライフ サイエンシーズ，インコーポレイテッド トコトリエノールまたはトコトリエノール濃縮抽出物を用いた広汎性発達障害の処置
HUE037592T2 (hu) 2009-08-26 2018-09-28 Bioelectron Tech Corp Eljárások cerebrális ischemia megelõzésére és kezelésére
WO2011041452A2 (en) 2009-10-01 2011-04-07 Ampere Life Sciences, Inc. Mouse model for identifying compounds for the treatment of oxidative stress
WO2011082355A1 (en) 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
US8464722B2 (en) 2010-03-04 2013-06-18 Medline Industries, Inc. Folded telescopic equipment drape and method of folding and using the same
US20110263720A1 (en) 2010-03-09 2011-10-27 Penwest Pharmaceuticals Co. Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same
WO2011113018A1 (en) 2010-03-12 2011-09-15 Ampere Life Sciences, Inc. Measurement and control of biological time
BR112012025558A2 (pt) 2010-04-06 2016-06-28 Edison Pharmaceuticals Inc tratamento para a ataxia-telangiectasia
US20130109759A1 (en) 2010-04-27 2013-05-02 Edison Pharmaceuticals, Inc. Formulations of quinones for the treatment of ophthalmic diseases
US20120101169A1 (en) 2010-07-14 2012-04-26 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
BR112013002877A2 (pt) 2010-08-06 2016-05-31 Edison Pharmaceuticals Inc tratamento de doenças mitocondriais com naftoquinonas
EP2601168A4 (en) 2010-08-06 2013-12-04 Ampere Life Sciences Inc TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K
WO2012068552A1 (en) 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
WO2012154613A1 (en) 2011-05-06 2012-11-15 Edison Pharmaceuticals, Inc. Improved process for the preparation of d-alpha-tocotrienol from natural extracts
WO2012170773A1 (en) 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
WO2013006736A1 (en) 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
US20150057363A1 (en) 2011-07-06 2015-02-26 Guy M. Miller Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
WO2013013078A1 (en) 2011-07-19 2013-01-24 Edison Pharmeceuticals, Inc. Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
WO2014039862A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
EP2964182B1 (en) 2013-03-08 2018-02-14 Unilever PLC, a company registered in England and Wales under company no. 41424 of Resorcinol compounds for dermatological use
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
JP2016515526A (ja) 2013-03-15 2016-05-30 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
CA2912871A1 (en) 2013-05-31 2014-12-04 Edison Pharmaceuticals, Inc. Carboxylic acid derivatives for treatment of oxidative stress disorders
ES2912585T3 (es) * 2014-12-16 2022-05-26 Ptc Therapeutics Inc Formas polimórficas y amorfas de la (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociclohexa-1,4-dienil)butanamida
EP3233819A1 (en) 2014-12-16 2017-10-25 Bioelectron Technology Corporation Methods for chiral resolution of trolox
WO2016114860A1 (en) 2015-01-12 2016-07-21 Edison Pharmaceuticals, Inc. Quinones for protection against radiation exposure
US10745371B2 (en) 2015-12-16 2020-08-18 Ptc Therapeutics, Inc. Methods for enriching alpha-tocotrienol from mixed tocol compositions
CN113024369A (zh) 2015-12-17 2021-06-25 Ptc医疗公司 用于治疗氧化应急障碍的化合物
WO2017123823A1 (en) 2016-01-12 2017-07-20 Bioelectron Technology Corporation Alkyl-, acyl-, urea-, and aza-uracil sulfide:quinone oxidoreductase inhibitors
JP2019501974A (ja) 2016-01-12 2019-01-24 バイオエレクトロン テクノロジー コーポレイション チオスルフェートレベルを増加させるためのまたは硫化水素レベルを低下させるためのトコフェロールキノン誘導体およびトコトリエノールキノン誘導体
US20190241497A1 (en) 2016-10-28 2019-08-08 Andrew W. Hinman Methods for analyzing p-hydroquinone levels and ratios
WO2018093957A1 (en) 2016-11-15 2018-05-24 Bioelectron Technology Corporation 2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof cross reference to related applications
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
WO2018129411A1 (en) 2017-01-06 2018-07-12 Bioelectron Technology Corporation Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders
WO2018191732A1 (en) 2017-04-14 2018-10-18 Bioelectron Technology Corporation Methods and compositions for treatment of inflammation and oxidative stress
US20180333389A1 (en) 2017-04-14 2018-11-22 Bioelectron Technology Corporation Vitamin e compositions and methods of use therefor

Also Published As

Publication number Publication date
JP6810692B2 (ja) 2021-01-06
KR102626895B1 (ko) 2024-01-18
SG11201704968XA (en) 2017-07-28
US11304914B2 (en) 2022-04-19
AU2022202949A1 (en) 2022-05-26
JP7277061B2 (ja) 2023-05-18
EP3233786B1 (en) 2022-03-16
US20230364029A1 (en) 2023-11-16
JP2021185199A (ja) 2021-12-09
WO2016100579A1 (en) 2016-06-23
RU2017124714A3 (es) 2019-07-17
CN107531616A (zh) 2018-01-02
BR112017012988B1 (pt) 2023-10-03
US20220265578A1 (en) 2022-08-25
DK3233786T3 (da) 2022-05-09
SG10202003299PA (en) 2020-05-28
RU2770091C2 (ru) 2022-04-14
ES2912585T3 (es) 2022-05-26
US20210015765A1 (en) 2021-01-21
US20190307706A1 (en) 2019-10-10
PT3233786T (pt) 2022-05-06
CA2971252A1 (en) 2016-06-23
HUE058877T2 (hu) 2022-09-28
AU2020207880B2 (en) 2022-02-17
JP7111759B2 (ja) 2022-08-02
AU2015364640A1 (en) 2017-07-27
AU2020207880A1 (en) 2020-08-13
BR112017012988A2 (pt) 2018-01-02
US10251847B2 (en) 2019-04-09
JP2020111582A (ja) 2020-07-27
AU2020207880C1 (en) 2022-05-26
AU2015364640B2 (en) 2020-08-13
CN107531616B (zh) 2022-04-26
CN114702406A (zh) 2022-07-05
NZ733528A (en) 2021-07-30
JP2018500326A (ja) 2018-01-11
PL3233786T3 (pl) 2022-06-13
US11938101B2 (en) 2024-03-26
SI3233786T1 (sl) 2022-08-31
AU2022202949B2 (en) 2024-05-02
JP2022116352A (ja) 2022-08-09
MX2021009340A (es) 2021-09-08
RU2017124714A (ru) 2019-01-17
EP3233786A1 (en) 2017-10-25
EP4059922A1 (en) 2022-09-21
US10751302B2 (en) 2020-08-25
KR20170096139A (ko) 2017-08-23
IL252953A0 (en) 2017-08-31
US20180000749A1 (en) 2018-01-04
ZA201704639B (en) 2020-02-26

Similar Documents

Publication Publication Date Title
MX2021009340A (es) Formas amorfas y polimorficas de (r)-2-hidroxi-2-metil-4-(2,4,5- trimetil-3,6-dioxociclohexa-1,4-dienil)butanamida.
EP3675882A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP3837359A4 (en) METHODS AND COMPOSITIONS FOR TREATING MITOCHONDRIAL DISEASE OR MITOCHONDRIAL DISORDERS AND HETEROPLASMIA
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
IL298690B1 (en) Preparations and methods for suppressing masp-3 for the treatment of various diseases and conditions
EP3448398A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
EP3185876A4 (en) Compositions and methods for treatment of neurological disorders
GEP20197046B (en) Substituted oxopyridine derivatives
EP3481387A4 (en) METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
WO2014145116A3 (en) Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
EP3526319A4 (en) METHOD AND COMPOSITIONS AND FOR TREATING DISEASES AND DISORDERS OF THE CENTRAL VENTILATION SYSTEM
PH12019500494A1 (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
MX2018014114A (es) Derivados del sobetiroma.
EP3681477A4 (en) IMPROVED METHOD AND COMPOSITION FOR THE TREATMENT OF CONDITIONS, DISEASES OR DISORDERS SENSITIVE TO TRITERPENES
EP3507371A4 (en) METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM
EP3411031A4 (en) DETERERATED DOMPERIDONE COMPOSITIONS AND METHODS FOR DISEASE THERAPY
EP3681871A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF BRAIN INJURY
EP3554505A4 (en) METHODS FOR TREATMENT OF EYE DISEASES
WO2018081806A3 (en) Compositions and methods for impeding transcription of expanded microsatellite repeats
EP3737355A4 (en) COMPOSITIONS AND METHODS OF TREATING A NERVE INJURY
EP3720508A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF GENOMIC FOOTPRINT DISORDERS
EP3200828A4 (en) Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
EP3142674A4 (en) Methods and compositions for treatment of macrophage-related disorders
EP3526248A4 (en) COMPOSITIONS AND METHODS FOR TREATING LESIONS OF THE CENTRAL VENEER SYSTEM
WO2018045078A3 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING LYMPHATIC SYSTEM DISORDERS